EcoDrugPlus

Kinase Insert Domain Receptor

Ensembl ID : ENSMODG00000020673
Gene Symbol: KDR
5 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 5b

Ensembl ID : ENSMODG00000007760
Gene Symbol: KIF5B
5 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 2

Ensembl ID : ENSMODG00000003816
Gene Symbol: LOC100026095
4 Cross references
83 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 2

Ensembl ID : ENSMODG00000041901
Gene Symbol: LOC103097245
3 Cross references
84 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 6

Ensembl ID : ENSMODG00000025594
Gene Symbol: LOC103098786
3 Cross references
96 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 3

Ensembl ID : ENSMODG00000028822
Gene Symbol: LOC103099707
4 Cross references
84 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lysyl Oxidase Like 2

Ensembl ID : ENSMODG00000016806
Gene Symbol: LOXL2
2 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSMODG00000012335
Gene Symbol: MST1R
3 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 1 Receptor

Ensembl ID : ENSMODG00000049581
Gene Symbol: MC1R
2 Cross references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 3 Receptor

Ensembl ID : ENSMODG00000016430
Gene Symbol: MC3R
4 Cross references
138 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 4 Receptor

Ensembl ID : ENSMODG00000025063
Gene Symbol: MC4R
4 Cross references
121 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1a

Ensembl ID : ENSMODG00000004999
Gene Symbol: MTNR1A
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).